Results 231 to 240 of about 61,117 (342)

Benefits of Implantable Cardioverter–Defibrillator for Secondary Prevention in Patients With Organic Heart Disease

Annals of Noninvasive Electrocardiology, Volume 31, Issue 1, January 2026.
Three‐quarters of patients who underwent ICD/CRT‐D implantation for secondary prevention received appropriate ICD therapy and survived at least 1 year thereafter. In contrast, patients aged 70 or older and those with a history of ventricular fibrillation (VF) were less likely to benefit from secondary prevention with an ICD.
Rie Akagawa, Sou Otsuki, Minori Sakurazawa, Atsushi Kato, Hironori Furuse, Naomasa Suzuki, Yasuhiro Ikami, Yuki Hasegawa, Masaomi Chinushi, Takayuki Inomata   +9 more
wiley   +1 more source

A novel mineralocorticoid receptor blocker, CS-3150, improves insulin resistance and reduces inflammation in db/db mice. [PDF]

Korean J Physiol Pharmacol
Bavuu O, Fukuda D, Munkhjargal U, Ganbaatar B, Hara T, Yagi S, Soeki T, Sata M.   +7 more
europepmc   +1 more source

Tailoring Mineralocorticoid Receptor Antagonist Therapy in Heart Failure Patients: Are We Moving Towards a Personalized Approach? [PDF]

, 2017
João Pedro Ferreira, Robert J. Mentz, Anne Pizard, Bertram Pitt, Faı̈ez Zannad   +4 more
openalex   +1 more source

Adrenal Insufficiency During Treatment With Immune‐Checkpoint Inhibitors: How to Simplify the Diagnostic Pathway?

Clinical Endocrinology, Volume 104, Issue 1, Page 39-46, January 2026.
ABSTRACT Objective and Background Early identification of adrenal insufficiency (AI) during immune‐checkpoint inhibitors (ICIs) is crucial to prevent life‐threatening consequences; however, the diagnosis is challenging. Design, Patients and Measurement In this prospective observational study, ICI‐treated cancer patients with morning serum cortisol (SC)
Alice Nervo, Giovanni Gruosso, Marta Marino, Enrica Migliore, Matteo Rubiolo, Elisa Vaccaro, Emanuela Arvat   +6 more
wiley   +1 more source

Efficacy and safety of mineralocorticoid receptor antagonists in heart failure: a meta-analysis of randomized controlled trials. [PDF]

BMC Cardiovasc Disord
Wu J, Pei Y, Wu J, Huang Y.
europepmc   +1 more source

Mass Spectrometric Measurements of 11‐Deoxycortisol, Androstenedione and Dehydroepiandrosterone Are Superior to Cortisol to Assess Selectivity of Non‐Stimulated Adrenal Vein Sampling

Clinical Endocrinology, Volume 104, Issue 1, Page 10-18, January 2026.
ABSTRACT Objective Successful adrenal venous sampling (AVS) is traditionally assessed using the ratio of cortisol in adrenal to peripheral venous plasma to calculate the selectivity index. With mass spectrometry other steroids can be simultaneously measured that may improve numbers of apparent successful sampling procedures.
Francesco Alessi, Christina Pamporaki, Mirko Peitzsch, Georgiana Constantinescu, Hanna Remde, Lydia Kürzinger, Carmina T. Fuss, Manuel Schulze, Sybille Fuld, Sradha Kotwal, Jun Yang, Martin Reincke, Felix Beuschlein, Jacques W. M. Lenders, Graeme Eisenhofer   +14 more
wiley   +1 more source

Renin-guided therapy with mineralocorticoid receptor antagonists in primary aldosteronism: feasibility study (RETAME-PA) - a clinical research protocol for a randomised controlled trial. [PDF]

BMJ Open
Merabtine A, Leung AA, Kline GA, Dubrofsky L, Hundemer GL, Goupil R.   +5 more
europepmc   +1 more source

Steroids:Modulators of inflammation and immunity [PDF]

, 2010
Chapman, Karen E, Odermatt, Alex
core   +1 more source

Eplerenone improves kidney function and cardiac performance in obese male mice

Diabetic Medicine, Volume 43, Issue 1, January 2026.
Abstract Aims Renin‐angiotensin‐aldosterone system (RAAS) activation mediates obesity‐associated cardiorenal dysfunction. Due to an incomplete understanding of the molecular mechanisms, the clinical use of RAAS antagonism in obesity‐associated cardiometabolic complications remains uncertain.
Ayman K. Banah, Bingxue Qi, Ryan Koh, Alexander Lawlor, Tianzhen Wang, Vishal Musale, Joanne Mains, Colin E. Murdoch, Li Kang   +8 more
wiley   +1 more source

Addressing unmet needs for chronic kidney disease treatment in type 1 diabetes: A review

Diabetes, Obesity and Metabolism, Volume 28, Issue 1, Page 16-26, January 2026.
Abstract Chronic kidney disease (CKD) is a serious complication occurring in nearly one of three people with type 1 diabetes (T1D). Major therapeutic advances have been made in the management of CKD for people with type 2 diabetes (T2D), thereby improving their kidney, cardiovascular, and survival outcomes.
Katherine R. Tuttle, Linong Ji, Chantal Mathieu, Jonathan Rosen   +3 more
wiley   +1 more source